904324-58-9

Upstream product

• 51987-73-6 (S)-2-tert-butoxycarbonylamino-3-phenyl-propionic acid methyl ester 
• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 
• 63-91-2 L-phenylalanine 
• 72155-45-4 Boc-L-phenylalaninal 
• 124818-94-6 ethyl (2E,4S)-4-[(tert-butoxycarbonyl)amino]-5-phenylpent-2-enoate 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 195867-20-0 (4S)-4-[(tert-butoxycarbonyl)amino]-5-phenylpentanoic acid 

Downstream Products

• 904324-65-8 [1-benzyl-4-(5-bromo-pyridin-3-yloxy)-butyl]-carbamic acid tert-butyl ester 
• 1643565-38-1 C₁₆H₂₄N₄O₂ 
• 1643565-41-6 C₁₉H₂₆N₄O₂ 
• 1643565-09-6 (R)-tert-butyl 6-benzyl-6,7,8,9-tetrahydro[1,2,3]triazolo[1,5-a][1,4]diazocine-5(4H)carboxylate 
• 1643565-35-8 C₂₃H₃₁NO₅S 
• 904324-80-7 {1-benzyl-4-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-butyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

A rapid entry to amino acid derived diverse 3,4-dihydropyrazines and dihydro[1,2,3]triazolo[1,5-a]pyrazines through 1,3-dipolar cycloaddition

An efficient, general and practical synthesis of diverse 3,4-dihydropyrazines, 6,7-dihydro-[1,2,3]triazolopyrazines and 7,8-dihydro-[1,2,3]triazolodiazepines through intramolecular 1,3-dipolar cycloaddition from amino acid derived common intermediates with high yields is described. Moreover, one-pot access to optically active 3-aryl substituted 6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazines in the palladium-copper co-catalytic system has also been achieved in this work. The easy substrate availability and operational simplicity make the process suitable for further exploration. This journal is the Partner Organisations 2014.

Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase

Based on lead compounds 2 and 3 a series of 3,5-disubstituted pyridines have been designed and evaluated for inhibition of AKT/PKB. Modifications at the 3 position of the pyridine ring led to a number of potent compounds with improved physical properties, resulting in the identification of 11g as a promising, orally active Akt inhibitor. The synthesis, structure-activity relationship studies, and pharmacokinetic data are presented in this paper.